Here, we report the results of a phase 1b study that investigated the combination of SPARTA, with or without CAN, and various PDC regimens to determine the recommended doses and regimens for expansion and further evaluation of the safety and efficacy of these combinations in advanced NSCLC with PD-L1-unselected with squamous and non-squamous histology. This evidence concerns the gene CD274 and non-small cell lung carcinoma.